Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: P.M.Freedman who wrote (1001)	6/9/1999 7:54:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 1686

Those repurchased BGEN shares were still able to be accounted as Biogen's cash holdings A company's own repurchased stock is not an asset (like stock in other companies), and will never be shown as part of their "cash holdings." As for whether Avonex has saturated the market, the following NY Times article is very much on point: nytimes.com June 8, 1999 Experts Ask Why So Few Take Drugs for M.S. By DENISE GRADY our months ago, Valerie Millerick finally made a decision that she had been putting off for years: She began taking weekly injections of a drug called Avonex, to treat multiple sclerosis. ... Peter